Novo Nordisk Signs Autoimmune Disease License Agreement with Janssen
May 20 2015 - 11:07AM
Dow Jones News
LONDON--Danish pharmaceuticals group Novo Nordisk A/S
(NOVO-B.KO) Wednesday said it has signed an agreement with U.S.
drug group Janssen Biotech, Inc. for Janssen to acquire an
exclusive global license to further develop and commercializes a
clinical program focused on therapy within autoimmune diseases.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter:
@RoryGallivan
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Sep 2023 to Sep 2024